Altrova Health

Altrova Health Launches O-Spray Needle-Free Sublingual Product Line and Provides Corporate Update

Altrova Health Launches O-Spray Needle-Free Sublingual Product Line and Provides Corporate Update

CSE: ROVA | OTCQB: SSPLF | FSE: QM4

Overview

Altrova Health Inc. (CSE: ROVA | OTCQB: SSPLF | FSE: QM4) announced the launch of its O-Spray™ product line, a needle-free sublingual oral spray platform targeting weight management, erectile dysfunction, menopause-related care, and other therapeutic indications. The company described the launch as a core strategic initiative following its recent corporate rebrand from Safe Supply Streaming Co. Ltd., effective May 1, 2026.

According to the press release, O-Spray utilizes an airless metered-dose pump designed for quick sublingual absorption within a 10-minute window. The product requires no needles, preparation, or refrigeration, and is shelf-stable at room temperature.

Key Highlights

  • Launch of the O-Spray™ needle-free sublingual oral spray product line across multiple therapeutic categories including weight management, erectile dysfunction, and menopause-related care
  • O-Spray features an airless metered-dose pump with sublingual absorption within a 10-minute window, requiring no needles, preparation, or refrigeration
  • The global GLP-1 receptor agonist market was valued at USD $53.5 billion in 2024 and is projected to reach USD $315 billion by 2035, representing a 17.5% CAGR, according to the company
  • The Canadian GLP-1 market is projected to grow from USD $2.1 billion in 2025 to USD $6.6 billion by 2033 at a 14.2% CAGR
  • Injectable administration accounts for 83% of the global GLP-1 market, with 24% of Canadian adults reporting needle phobia and 94.1% of needle-phobic adults preferring non-invasive alternatives
  • The company mutually terminated its previously announced agreement with Healthy Sprays, effective May 5, 2026, with full mutual releases exchanged and no additional payments made

Strategic Context

CEO Geoff Benic stated that the O-Spray launch positions Altrova Health within a large and rapidly expanding market for non-injectable drug delivery. The company cited research indicating that nearly one in four Canadian adults experiences needle phobia, representing what it described as a significant barrier to treatment adoption in the GLP-1 space where injectable formats currently dominate.

The termination of the Healthy Sprays agreement, originally signed on November 21, 2025, was described as a mutual decision. The company stated that the agreement was rescinded in its entirety, with full mutual releases exchanged and no additional payments required by either party.

Market Context

  • Global GLP-1 receptor agonist market: USD $53.5 billion (2024), projected USD $315 billion by 2035 at 17.5% CAGR
  • Canadian GLP-1 market: USD $2.1 billion (2025), projected USD $6.6 billion by 2033 at 14.2% CAGR
  • Injectable administration: 83% of global GLP-1 market share (2024)
  • Needle phobia prevalence: 24% of Canadian adults; 94.1% of needle-phobic adults prefer non-invasive alternatives

What to Watch Next

  • Commercialization progress and distribution strategy for the O-Spray product line across its target therapeutic categories
  • Regulatory pathway updates for sublingual delivery formulations
  • Further corporate developments following the rebrand to Altrova Health Inc.

About Altrova Health Inc.

Altrova Health Inc. (formerly Safe Supply Streaming Co. Ltd.) is a Toronto-based Canadian public company listed on the CSE (ROVA), OTCQB (SSPLF), and FSE (QM4). The company is building a technology-driven platform across detection, protection, treatment, and wellness verticals. Its current product portfolio includes the O-Spray sublingual oral spray line, the NIRLAB NIRLIGHT drug analysis device (exclusive Canadian distribution), and the ToxiShield fentanyl and drink-spiking detection product line.

Read the full press release here.

Disclaimer and Forward-Looking Statements

The information contained herein is provided by ArcStone Financial Pulse Inc. (“ArcStone Financial Pulse”), a subsidiary of ArcStone Securities and Investments Corp. (“ArcStone”), for informational purposes only. It is not, and under no circumstances should it be construed as, an offer to sell or a solicitation of an offer to buy any securities or other financial instruments in any jurisdiction. This content is not a research report within the meaning of FINRA Rules 2241 or 2242 and does not constitute a research report under any applicable securities laws.

Certain statements contained herein may constitute “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements are based on current expectations, estimates, and assumptions that involve known and unknown risks and uncertainties which may cause actual results or developments to differ materially from those expressed or implied. These statements often include words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “target,” or similar expressions. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Except as required by law, ArcStone undertakes no obligation to update or revise any forward-looking information.

This content is not intended as investment advice or a recommendation to buy or sell any security and does not take into account the investment objectives, financial situation, or needs of any individual. Investors should consult their own professional advisors before making any investment decisions.

ArcStone Securities and Investments Corp. is not a registered broker-dealer and does not provide investment advice or recommendations. All registrable activities in the United States are conducted through ArcStone Securities LLC (CRD# 306029) and Kingswood Capital Partners LLC (CRD# 288898), both FINRA-registered broker-dealers, members SIPC. ArcStone Canada Inc. is not registered as a dealer in any Canadian jurisdiction; registrable dealing activities in Canada are conducted through appropriately registered affiliates. ArcStone Financial Pulse Inc. is owned by the same parent entity as ArcStone Securities LLC and ArcStone Kingswood, the investment banking division of Kingswood Capital Partners LLC. This common ownership represents a structural conflict of interest. The issuer featured in this article (the “Company”) may be a current or former client of ArcStone or any of its subsidiaries and affiliates. Where ArcStone or its subsidiaries and affiliates have received or have been promised consideration for services provided to the Company, such consideration may include cash, stock, stock options, warrants, and/or Restricted Stock Units (RSUs) for the provision of corporate advisory, investor relations, digital media, or capital markets consulting services. This relationship represents a potential conflict of interest, as ArcStone may be perceived to have an incentive to present the Company in a favorable light. The principals, directors, officers, employees, and related entities of ArcStone and its affiliates may, from time to time, own, buy, or sell securities or derivatives of the Company or its affiliates.

Read more